Casaasdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso
Last updated 22 dezembro 2024
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
PDF) The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study - Pavelka - 2020 - ACR Open Rheumatology - Wiley Online Library
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex, Arthritis Research & Therapy
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF Inhibitor Therapy, Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
IJMS, Free Full-Text
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Spondyloarthritis in Colombia - Wilson Armando Bautista-Molano by Wilson Bautista-Molano - Issuu
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial - The Lancet
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison - Document - Gale OneFile: Health and Medicine
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
PDF) Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Analysis of Single‐Cell Transcriptome and Surface Protein Expression in Ankylosing Spondylitis Identifies OX40‐Positive and Glucocorticoid‐Induced Tumor Necrosis Factor Receptor–Positive Pathogenic Th17 Cells - Yi - 2023 - Arthritis & Rheumatology - Wiley
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Full article: POSTER PRESENTATIONS
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Poster Abstract Presentation Abstracts - 2023 - International Journal of Rheumatic Diseases - Wiley Online Library
Recomendado para você
você pode gostar

© 2014-2024 faktorgumruk.com. All rights reserved.